Supplementary Figure 15 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Year: 2024
Type: supplementary-materials
Abstract: In vitro analysis of MET H1094Y and F1200I mutations in PC9 cells. (A) Establishment of NSCLC cancer cell lines expressing MET TKD mutations. PC9 cells were transduced with wild-type (WT) MET (as control) and MET H1094Y and F1200I. (B) Growth inhibition assay of PC9 cells in response to EGFR inhibition with osimertinib. (C) Cell proliferation and relative apoptosis were monitored under EGFR inhibition with osimertinib (300 nM). (D) Phosphorylation of MET, EGFR, AKT, and ERK was analyzed in PC9 cells expressing MET TKD mutants. PC9 cells were treated with osimertinib (1 μM) with or without capmatinib (1 μM) for 48 hrs. (E) IC50 values of PC9 cells (upper table) and Ba/F3 cells (lower table) expressing MET TKD mutants in response to MET TKIs. PC9 cells were treated with gradient dose of MET TKI combined with a fixed dose of osimertinib (100 nM) for 72 hrs.
Authors: Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K. Lee, Joao V. Alessi, Adriana Barrichello, Victor R. Vaz, Giuseppe Lamberti, Alessandro Di Federico, Malini M. Gandhi, Dimitris Gazgalis, William W. Feng, Jie Jiang, Simon Baldacci, Marie-Anaïs Locquet, Felix H. Gottlieb, Monica F. Chen, Elinton Lee, Danielle Haradon, Anna Smokovich, Emma Voligny, Tom Nguyen, Vikas K. Goel, Zachary Zimmerman, Sumandeep Atwal, Xinan Wang, Magda Bahcall, Rebecca S. Heist, Sumaiya Iqbal, Nishant Gandhi, Andrew Elliott, Ari M. Vanderwalde, Patrick C. Ma, Balazs Halmos, Stephen V. Liu, Jianwei Che, Alexa B. Schrock, Alexander Drilon, Pasi A. Jänne, Mark M. Awad
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4401273993